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ABSTRACT The localization of dioxygen sites in oxygen-binding proteins is a nontrivial experimental task and is often
suggested through indirect methods such as using xenon or halide anions as oxygen probes. In this study, a straightforward
method based on x-ray crystallography under high pressure of pure oxygen has been developed. An application is given on
urate oxidase (UOX), a cofactorless enzyme that catalyzes the oxidation of uric acid to 5-hydroxyisourate in the presence of
dioxygen. UOX crystals in complex with a competitive inhibitor of its natural substrate are submitted to an increasing pressure of
1.0, 2.5, or 4.0 MPa of gaseous oxygen. The results clearly show that dioxygen binds within the active site at a location where a
water molecule is usually observed but does not bind in the already characterized speciﬁc hydrophobic pocket of xenon.
Moreover, crystallizing UOX in the presence of a large excess of chloride (NaCl) shows that one chloride ion goes at the same
location as the oxygen. The dioxygen hydrophilic environment (an asparagine, a histidine, and a threonine residues), its ab-
sence within the xenon binding site, and its location identical to a water molecule or a chloride ion suggest that the dioxygen site
is mainly polar. The implication of the dioxygen location on the mechanism is discussed with respect to the experimentally sug-
gested transient intermediates during the reaction cascade.
INTRODUCTION
UOX (uricase; EC 1.7.3.3) is a homotetrameric enzyme be-
longing to the purine degradation pathway, which catalyzes,
in the presence of molecular oxygen, the hydroxylation of
uric acid (1) to a primary intermediate that has been identiﬁed
as 5-HIU (2) (1–3) as shown in the following scheme:
This intermediate is further transformed to S-allantoin (3)
through a speciﬁc enzymatic cascade (4–6). UOX is present
in many species but is absent in humans and higher apes. This
emphasizes an evolutionary advantage: it has been suggested
that uric acid is a powerful antioxidant, so humans would
have less free radicals and thus less cancer as a result of aging
(7,8). As a consequence, the uric acid level in plasma is quite
elevated, and any higher pathological level may be lethal.
The Sanoﬁ-Aventis company produces and commercializes
UOX, ﬁrst extracted from Aspergillus ﬂavus and now ex-
pressed in Saccharomyces cerevisiae, to prevent hyperuri-
cemia that can happen during chemotherapies (9,10). The
x-ray structure of UOX shows that the homotetramer is
conserved in the crystal packing and presents a globular
structure crossed by a tunnel 12 A˚ in diameter and 50 A˚ long
(11). There are four identical active sites, each localized at
interfaces between symmetrical monomers.
The catalytic mechanism of UOX does not imply any
cofactor or metal ion. Several x-ray structures with or without
various inhibitors have been determined to unravel the active
site (12,13). Recently, the structure of the functional enzyme
solved in the presence of its natural substrate, uric acid, leads
to an [S]-allantoin–UOX complex showing that the enzyme
has afﬁnity for the ﬁnal product of the degradation cascade
(14). In the vicinity of the active site, separated by a single
valine residue, is a large hydrophobic cavity where hydro-
phobic and anesthetic gases such as xenon or nitrous oxide
speciﬁcally bind (15,16), the function of which remains un-
known. Xenon is often used as a probe for dioxygen-binding
sites (17,18), and it was hypothesized that the xenon binding
cavity already characterized in UOX could serve for dioxy-
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gen storage. In this context, we have developed a new x-ray
crystallographic technique using pure oxygen under high
pressure with the aim of directly localizing the dioxygen-
binding site in UOX. In parallel, a structure under high
concentration of NaCl, known as a good oxygen surrogate
(19), was solved to conﬁrm the usefulness of halides and
xenon in probing oxygen sites.
MATERIALS AND METHODS
Puriﬁed recombinant A. ﬂavus UOX, expressed in S. cerevisiae, and 8-AZA
were supplied by Sanoﬁ-Aventis (Montpellier, France). The crystals of the
UOX/8-AZA complex were grown following the batch technique at room
temperature: 10–15mg/ml protein with an excess of 8-AZA (0.5–2mg/ml) in
50 mM Tris/HCl, pH 8.5, in the presence of 5–8% w/v PEG 8000 and NaCl
0.05 M (20). This led to orthorhombic crystals within 24–48 h.
X-ray data collections were carried out at the BM 14 beamline (European
Synchrotron Radiation Facility, Grenoble, France) at a wavelength of 0.972 A˚
and operating in a 16-bunch mode, using a MAR CCD detector (Evanston,
IL). The temperature was set to 277 K. Crystals were mounted in a quartz
capillary ﬁtted to a specially designed pressurization cell (21,22). The cell
initially designed for inert gas was adapted for the use of pure oxygen,
considered as a more aggressive component (stainless steel instead of PEEK
tubing). Crystals were kept under constant oxygen pressure maintained
during all data collections. Three data sets were collected under oxygen
pressure at 1.0 MPa, 2.5 MPa, or 4.0 MPa (10, 25, or 40 bars). No important
decay of crystals was observed under dioxygen pressure, even at a pressure of
4.0 MPa, showing that at least UOX crystals can tolerate oxygen with little
damage, probably because of the attenuated 16-bunch mode of the syn-
chrotron. Data were integrated and scaled by the HKL package of programs
(23). Cell parameters were reﬁned by the postreﬁnement technique im-
plemented in SCALEPACK. Final absolute data scaling was carried out with
programs of the CCP4 package (24).
A native UOX structure, the data of which were collected in the same
conditions, was used as a starting model for rigid body reﬁnement after re-
moval of the water molecules and the ligand. Structure reﬁnements were
carried out by REFMAC (25) from the CCP4 package.
Crystals of UOX have also been grown following the standard procedure
previously described but with a NaCl concentration increased to 0.3 M and
PEG 8000 up to 15% (w/v). In these conditions, small diamond-shaped
crystals develop to their ﬁnal size within a week. Data were recorded on the
BM 30 Beamline (ESRF) at a wavelength of 0.963 A˚. The temperature was
set to 100 K. Data were integrated with MOSFLM (26) and then converted
to structure factors and scaled as usual (24). The same reference native
coordinate ﬁle previously recorded was used, after removal of all water and
ligands as the starting point of the reﬁnements, carried out with
SHELXL (27).
The graphics program O (28) was used to visualize the j2Fobs  Fcalcj,
jFobs  Fcalcj and omit electron-density maps and for manual reﬁtting. A
summary of the data collections and reﬁnement statistics is shown in Table 1.
The atomic coordinates and structure factors have been deposited with the
Protein Data Bank, accession numbers: 2ZKA, 2ZKB, and 3CKS for 1.0,
2.5, and 4.0 MPa oxygen pressure, respectively, and 3CKU for the structure
with a chloride ion.
RESULTS
Comparison of the native UOX structure and the three
structures under oxygen pressure indicates that the hydro-
phobic cavity, which can bind one xenon atom or two nitrous
TABLE 1 Crystallographic data collection and reﬁnement statistics
Structure UOX/8-AZA with oxygen UOX/8-AZA/Cl
O2 pressure (MPa) 1 2.5 4 —
Temperature (K) 277 277 277 100
Unit cell parameters (A˚)
a 80.17 79.75 80.29 78.99
b 96.23 96.29 96.15 94.98
c 105.41 105.43 105.35 104.38
Resolution range (A˚) 70–1.61 70–1.61 70–1.70 70–1.70
(1.70–1.61) (1.70–1.61) (1.96–1.70) (1.79–1.70)
Unique reﬂections (n) 52,656 (5,211) 52,204 (5,133) 40,386 (4,249) 43,251 (6,302)
Rsym (%) overall* 5.4 (26.5) 5.5 (37.4) 5.7 (31.7) 4.7 (8.4)
Completeness (%) 99.4 (99.0) 98.8 (97.6) 89.4 (95.7) 99.6 (100)
I/s(I) 17.0 (3.0) 11.0 (2.0) 15.0 (3.5) 22.0 (13.7)
Redundancy 4.6 (4.1) 3.4 (3.0) 3.8 (3.8) 3.5 (3.5)
Reﬁnements
Resolution range (A˚) 15–1.61 15–1.67 15–1.70 50–1.70
Rwork (%)
y 17.2 17.1 17.1 19.3
Rfree (%)
z 19.1 19.0 20.1 21.1
Nb of waters 217 199 181 275
Ligand and thermal B factor (A˚2) O2 O2 O2 Cl

16.5–19.7 18.8–19.4 16.3–17.7 10.6
Weighted rmsd from ideality
Bond length (A˚) 0.011 0.013 0.012 0.035
Bond angle () 1.489 1.515 1.508 0.085
All structures are orthorhombic; in the I222 space group. Highest resolution shell is shown in parentheses.
*Rsym is deﬁned as +h;k;l+ijIiðh; k; lÞ  Iiðh; k; lÞj=+h;k;l+iIiðh; k; lÞ where Ii(h,k,l) is the ith observation of reﬂection h,k,l and ÆI(h,k,l)æ is the weighted mean
of all observations (after rejection of outliers).
yRwork is deﬁned as +jFoj  jFcj=+jFoj and indicates the accuracy of the model.
zRfree is a cross validation residual calculated using 5% of the native data, which were randomly chosen and excluded from the reﬁnement.
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oxide molecules (16), remains empty whatever oxygen
pressure is used, showing that dioxygen and xenon (or ni-
trous oxide) do not share the same binding site. The role of
this large hydrophobic cavity is not then as a storage location
for oxygen, although we cannot rule out a transient docking
pathway for oxygen along its access to its reactive location.
The active site where inhibitors bind is located at the in-
terface between two symmetrical monomers. In all the known
UOX structures solved in the I222 space group (including
8-AZA, 9-methyl uric acid, oxonic acid, diamino-uracil,
guanine (12,13), allantoin (14), xanthine, and 8-nitroxanthine
(L. Gabison, T. Prange´, N. Colloc’h, M. El Hajji, B. Castro,
and M. Chiadmi, unpublished data)), a water molecule called
W1 is always observed, tightly hydrogen bonded to the side
chains of asparagine-254 and threonine-57* from the sym-
metric monomer, at a distance of ;3.5 A˚ above the C4-C5
bond of the inhibitors (see Fig. 3 B). In the x-ray structure
under 1.0 MPa (10 bars) oxygen pressure, when W1 is ﬁtted
within the electronic density, its resulting B-factor is lowered
below 10 A˚2. Moreover, two residual peaks appear on both
sides in the Fobs  Fcalc map. A dioxygen molecule, instead
of W1, can better ﬁt the omit-map density, with a full occu-
pancy factor and resulting B-factors of;18 A˚2, equivalent to
those of the neighboring atoms (Fig. 1). After further re-
ﬁnement cycles, no residual peaks emerge from subsequent
jFobs  Fcalcj maps.
In the structures with 2.0 MPa (20 bars) and 4.0 MPa (40
bars) oxygen pressure, a dioxygen molecule with identical
occupancy and similar B-factors is also observed at the same
location, showing that dioxygen fully occupies its binding
site as early as 1.0 MPa. The position of the dioxygen mol-
ecule has been optimized so that the thermal B-factors of the
two oxygen atoms are of the same order (Table 1). In the three
structures, the optimized reﬁned orientation of the dioxygen
molecule is slightly different. At 1.0 MPa oxygen pressure,
the dioxygen leans toward the inhibitor C5 atom (angle of
109 between O2 and C5); at 2.5 MPa oxygen pressure, the
dioxygen is almost parallel to the inhibitor (angle of 83
between O2 and C5); and at 4.0 MPa oxygen pressure, the
dioxygen leans toward the inhibitor C4 atom (angle of 64
between O2 and C5, angle of 108 between O2 and C4). This
is an indication that the dioxygen molecule is rather mobile in
its binding pocket but always positioned above the C4-C5
bond of the inhibitor. In the structure with 1.0 MPa oxygen
pressure, the O2 molecule is ideally oriented for the oxidative
reaction, with a distance of 3.26 A˚ between one of the oxygen
atoms and the inhibitor C5 atom (Fig. 1). A gas pressure 10
times the physiological pressure was advocated as a necessity
to saturate all binding sites in the crystal and to allow its
visualization because of the crystallography technique em-
ployed (29). The structure with 1.0 MPa oxygen pressure is
then likely to be the one that best represents the position of
the dioxygen at ambient oxygen pressure.
Carbon monoxide has been known for a long time to be a
powerful inhibitor of oxygen. In a structure previously col-
lected with 5.0 MPa pressure of carbon monoxide (data not
shown), the water molecule W1 is still present, and no gas
molecule can be localized either in the inert gas binding
cavity or in the active site of UOX, showing that the binding
site above the inhibitor remains rather speciﬁc to dioxygen.
In the structure solved at high NaCl concentration, a
chloride ion is clearly observed at the location of the W1
molecule. However, the larger size of the Cl ion leads to a
slight widening of the active site, with an elongated distance
between the Asn-254 and the Thr-57* side chains (5.91 A˚
instead of 5.48 A˚ with W1 and 5.65 A˚ with the dioxygen
molecule) and between Thr-57* and Lys-10* side chains
chains (3.23 A˚ instead of 2.86 A˚ withW1 and 2.93 A˚ with the
dioxygen molecule).
DISCUSSION
Implication in probing dioxygen-binding site
Probing dioxygen-binding sites in oxidase or heme or non-
heme proteins that require molecular oxygen for their
mechanism is usually investigated through indirect tech-
niques. One of the methods consists of the use of xenon under
pressure. Xenon is the prototype of a nonpolar gas, with a
similar size to oxygen (4.3 A˚ diameter for xenon, 4.3 and 3 A˚
diameter for dioxygen), and it has been hypothesized that
oxygen would also prefer equivalent hydrophobic environ-
ment as xenon does (17,18,30–32). It is well known that Xe-
binding sites are hydrophobic cavities, often close to the
active site, and have been proposed to serve as pathways or
speciﬁc binding sites for molecular oxygen, as for example in
myoglobin (30), cytochrome P450 (31), hydroxybenzoate
hydroxylase (18), or copper amine oxidase (17,32). How-
FIGURE 1 Omit map calculated by subtracting dioxygen phase contri-
bution. The dioxygen molecule, observed here in the structure with 1.0 MPa
(10 bars) oxygen pressure, is located within the active site above the
inhibitor mean plane, surrounded by three conserved residues (Thr-57*,
Asn-254, and His-256) (Contour levels at 3s above the average back-
ground). This ﬁgure was produced with the visualization software PYMOL
(DeLano Scientiﬁc, San Carlos, CA).
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ever, in the last case, because the putative oxygen-binding
cavity does not bind xenon, the authors concluded that this
cavity is not hydrophobic enough for xenon (17).
Recently, halide ions have also been used as dioxygen
surrogates based on similar polarizability and similar volume
to oxygen, with, however, different geometric criteria. This
has been proposed in the case of FGE, where a small cavity
beneath the disulﬁde-bond substrate can be occupied by a
chloride, a bromide, or an iodide ion (19,33). This small cavity
(32 A˚3) was proposed to be the oxygen-binding cavity despite
its hydrophilic character (it is lined with three cysteine, serine,
and tryptophan side chains plus a water molecule).
Here in UOX, we observe that oxygen under pressure does
not bind the already characterized xenon (or nitrous oxide)
binding cavity but is located within the active site in a polar
environment, at a location usually occupied by a water
molecule, above the ligand. Regarding halide ions, we ob-
serve that chloride is located at the same place as dioxygen,
conﬁrming that chloride is effectively a good candidate for
probing oxygen-binding sites. Obviously, the larger size of
the chloride ion and its permanent negative charge slightly
modify the oxygen-binding site geometry as observed when
both active site coordinates are superimposed. It is interesting
to note that the polar environment of dioxygen in UOX is
similar to the proposed dioxygen environment in FGE (33).
These ﬁndings question the use of xenon as a speciﬁc probe
for oxygen-binding sites.
We are aware that compressed oxygen could represent a
highly aggressive environment, but at least in the case of
UOX, because no major degradation of crystals on oxygen
pressure was observed, it is believed that such an experi-
mental approach could be extended to other biological oxi-
dative systems because it directly evidences speciﬁc binding
sites of dioxygen.
Implication for the catalytic mechanism of
cofactorless UOX
The experimentally observed position of the dioxygen mol-
ecule in its speciﬁc binding site, with one oxygen atom close
to the C5 atom of 8-AZA (,3.3 A˚), gives new insights into
the understanding of the UOX mechanism. This particular
mechanism has been investigated for a long time (34) but
remains interesting because this oxidase requires no cofactor
or metal ion (35). In 1952, pioneering isotopic experiments
showed that the oxygen atoms of hydrogen peroxide derive
from dioxygen and that the oxygen atom attached to C5 in the
product derives from water (34). The reaction sensitive to pH
presents an optimum in basic condition (pH ;8–9). NMR
studies have shown that the true product of UOX is a meta-
stable intermediate that has been identiﬁed as 5-HIU (1–3). In
addition, spectroscopic characterization of the early step of
the reaction by transient-state kinetics and trapping experi-
ments suggested that urate hydroperoxide would be an early
intermediate between uric acid and 5-HIU (36).
Oxidases requiring no metal ion or prosthetic group for
catalysis present the challenging problem of how molecular
oxygen is activated. In cofactorless oxygenases, such as the
oxoquinaldine and oxoquinoline dioxygenases (Hod and
Qdo, respectively) (37), in ActVA-Orf6 mono-oxygenase
whose x-ray structure has been solved (38), or in FGE (33),
dioxygen and substrate activation is performed exclusively
by residues of the catalytic site, probably through a direct
electron transfer from the deprotonated substrate to molec-
ular oxygen (39). It has also been suggested that they could
proceed via single-electron transfer steps through a hydro-
peroxide intermediate (37,39,40), as for the reaction of
reduced ﬂavins and pterins with dioxygen, even if this
mechanism has not been ﬁrmly established for all cases (41).
UOX presents a number of similarities with pterin-binding
proteins (42), and it is worth noting that their mechanisms
could be related.
In the case of UOX, a step-by-step mechanism was pro-
posed based on biochemical and x-ray diffraction experi-
ments (36,40,43–45). In the proposed mechanism (Fig. 2),
the enzyme ﬁrst generates the urate dianion (2) from the urate
monoanion (1) while reaching the active site. Then, the
addition of dioxygen leads to 5-hydroperoxyisourate (3),
followed by the collapse of 5-hydroperoxyisourate to lead
to dehydrourate (4). Finally, the hydroxylation of the de-
hydrourate intermediate leads to 5-HIU (5).
The x-ray structure under oxygen pressure shows that the
dioxygen molecule is localized at the same position as the
W1 water molecule, conﬁrming that the reaction proceeds
following a step-by-step mechanism with implication of a
hydroperoxide intermediate (3 in Fig. 2).
In addition, we know now that the natural substrate, uric
acid, occupies the same position as the different inhibitors
in the active site of UOX (L. Gabison, T. Prange´, N. Colloc’h,
M. El Hajji, B. Castro, and M. Chiadmi, unpublished data).
We can then suggest that the di-ionic state of the natural
substrate is the [N3 N7] dianion (12) (species 2 in Fig. 2)
rather than the [N3 N9] dianion as initially proposed (36).
This assumption is based on the donor/acceptor complexa-
tion scheme observed on the N7/C8/O8 side of urate, where
the two donors are two main-chain amido hydrogens (Fig.
3 A). This implies a negative charge delocalized on the N7/O8
atoms of urate. This is in agreement with quantum mechanic
calculations showing that the [N3 N7] dianion once com-
plexed has the lowest ionization potential and is the most able
to give one electron to an acceptor species spontaneously (46).
The enzyme would thus need a general base to abstract the
N7 proton. The structures under oxygen pressure, the already
solved structures with different uric acid-like inhibitors, and
the recently solved structure in the presence of uric acid do
not show how the enzyme abstracts the N7 proton. We can
only draw some hypothesis based on the surroundings of the
substrate. Above the substrate, the water molecule W1 is
tightly held by a molecular tweezers built by the side chains
of two residues that belong to two different subunits, Asn-
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254 and Thr-57*. In a previous study (44), the two connected
residues Thr-57* and Lys-10* were mutated and found to
play a role in the catalysis. In addition, the Lys-10* side
chain, itself hydrogen-bonded to the His-256 side chain (Fig.
3 B), displays a much lower pKa (pKa 6.2) than usual in free
solution (pKa 10), as deduced from PropKa calculations (47).
We can then propose that the water molecule W1, together
with the Thr-57* activated by the proton relay with the Lys-
10* and His-256, are implicated in the proton abstraction,
even if we do not understand how, because both theW1water
molecule and the Thr-57* side chain are not in the plane of
the substrate.
No mutation has yet been done to conﬁrm the His-256 im-
plication in the catalytic mechanism. In the cofactorless Hod, a
conserved histidine was also proposed to act as a general base
to generate a dianion on binding of the substrate; its mutation to
an alanine leads to a drastic decrease in the catalytic activity
(37). Interestingly, the UOX/Cl structure shows that, when a
chloride ion is present in place of the dioxygen, the repulsive
negative charge of the chloride abolishes the hydrogen bond
between Thr-57* and Lys-10* side chains (Od-57*–Nz-10*
distance now increases to 3.23 A˚). This suggests that chloride
would also inhibit the reaction, a feature that was conﬁrmed
by kinetics experiments in high salt conditions with [NaCl].
0.3 M (L. Gabison, unpublished results).
The second step of the reaction would consist of the di-
oxygen addition to lead to 5-hydroperoxyisourate (species 3 in
Fig. 2) as a transient intermediate, analogously to other co-
factorless oxygenases (39). The structure of UOX under
oxygen pressure clearly shows that the dioxygen molecule is
ideally situated above the C4-C5 bond of the ligand (Fig. 1 and
Fig. 3 B), ready to oxidize the dianion. The short distance
between one of the dioxygen atoms and the urate C5 atom
(3.26 A˚) reinforces the hypothesis of an oxidation of the urate
dianion at the C5 atom to yield the 5-hydroperoxyisourate,
structurally conﬁrming a hydroperoxide intermediate.
The third step of the catalysis would be the collapse of
5-hydroperoxyisourate by elimination of hydrogen peroxide
to give the dehydrourate (species 4 in Fig. 2), an analog of
oxidized ﬂavin. This compulsory-order ternary complex
mechanism was already proposed in the case of Hod, where
the anionic substrate binds before dioxygen, and carbon
monoxide leaves the enzyme-product complex ﬁrst, followed
by the organic product (37).
Finally, the last step would consist of the hydroxylation
of the dehydrourate intermediate to yield the ﬁnal
product 5-HIU (species 5 in Fig. 2). This reaction is likely to
proceed in the enzyme active site because the 5-HIU
released by the enzyme is optically active (48). The water
molecule W1, observed in all x-ray structures determined up
to now, is perfectly positioned above the ligand and thus
becomes the ideal candidate for the last step of hydroxylation
(Fig. 3 B). In the last step, a reprotonation of 5-HIU
must occur before the release of the monoanionic product.
Fig. 3 B depicts the complete hydrogen bond network
around the substrate. In this extended network, the His-
256 side chain is not only hydrogen-bonded to Lys-10*
but also to a water molecule (W3), itself hydrogen-bonded to
the W2 water molecule. This latter molecule is always
observed hydrogen-bonded to the N9 atom of the substrate
(Fig. 3 B). Thus, the W2 molecule may be implicated in the
reprotonation of the dehydrourate intermediate, leading to
5-HIU. In the absence of W2, such as in the complex of
9-methylurate (12), this protonation is abolished, which
explains why 9-methyl uric acid is a competitive inhibitor of
the reaction.
FIGURE 2 Putativeurateoxidationcas-
cade. This suggested mechanism is de-
duced from the active site topology based
on structural results and known reported
spectroscopic data.
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Analogies with catalase
The different UOX x-ray structures support the hypothesis
that the active site is designed to bind O2 and H2O molecules
sequentially at the same location. This process is analogous
to what is observed in catalase, a protective enzyme that
removes hydrogen peroxide to protect cells against its dele-
terious effects. In mammals, catalase and UOX are colo-
calized in the peroxisomes of hepatic cells, where they are
responsible for crystalloid core formations (49,50). Catalase
also has an active site designed to bind two molecules suc-
cessively at the same site: H2O2 then H2O. The structure of an
inactive mutant complex with H2O2 has shown that two H2O2
molecules are located immediately above the heme, at the
location usually occupied in the native structure by two water
molecules (51). In all known heme catalase x-ray structures,
the presence and the relative orientation of a conserved His
and a conserved Asn on the distal side of the heme have been
highlighted (52,53). The active site on the distal side of the
heme in catalase and above the uric acid in UOX shows
similarities with, in both cases, a His and an Asn (see Fig. S1
in SupplementaryMaterial, Data S1). In the x-ray structure of
catalase in complex with H2O2 (51), one H2O2 molecule
takes the place of the ﬁrst water molecule, whereas in the
x-ray structure of UOX under dioxygen pressure described
here, dioxygen takes the place of W1. We can therefore
suggest that, in UOX, the two conserved residues Asn-254
and His-256 are likely to play a role in binding H2O2. Cat-
alase requires that H2O2 molecules gain a rapid access to the
deeply buried active sites through a highly selective hydro-
phobic channel (53) while the dioxygen product exits
through a separate channel (51). In the case of UOX, the
dioxygen entrance and the H2O2 exit pathways still need to
be investigated and may be different from the uric acid access
channel. Moreover, the catalytic reaction of UOX in the
presence of catalase is considerably accelerated by elimina-
tion of H2O2 (54,55). This suggests that dioxygen and then
hydrogen peroxide would share sequentially a common site
in UOX.
CONCLUSION
In conclusion, the structure of UOX solved under oxygen
pressure demonstrates the existence of a speciﬁc polar
binding site for dioxygen within the active site, above the
substrate location. This site can also bind either a water
molecule or a chloride ion. Moreover, oxygen does not bind
within the hydrophobic xenon binding cavity previously
characterized. The polar environment of oxygen questions
the use of xenon as probe for oxygen-binding sites. Oxygen-
pressurized x-ray crystallography might be an ideal method
to localize the dioxygen site with conﬁdence. The application
to the UOX case shows that the experimentally observed
oxygen molecule is ideally located above the substrate plane,
ready to oxidize the urate dianion, leading to a hydroperoxide
intermediate during the reaction cascade. Moreover, the lo-
cation of the dioxygen molecule at the same location as the
catalytic water molecule implies that the mechanism in which
oxygen and water bind sequentially to a common site located
above the substrate proceeds step by step. Further studies
FIGURE 3 Description of the active site built at the interface of two subunits
of UOX. (A) Because uric acid lies in the same position as uric-acid-like
inhibitors, it is stacked with Phe-159 and hydrogen-bonded to the enzyme
through a molecular tweezers composed by the conserved Arg-176 and Gln-
228. The Val-227 is, moreover, hydrogen-bonded to the substrate through its
main chain nitrogen and has its hydrophobic side chain lining the xenon-binding
cavity. The ﬁve-membered ring of uric acid is linked to a symmetrical monomer
of the enzyme through three hydrogen bonds: one between the N7 and the main
chain NH of Thr-57*, the second between the O8 and the main chain NH of
Asp-58*, and the third between the N9 and the conserved water molecule W2
(* indicates a symmetric residue). The survey of hydrogen atoms at the optimal
pH of the reaction (pH 7–10) within the active site would then favor a [N3
N7] urate dianion. For clarity, only polar hydrogen atoms are displayed. (B)
The active site showing the activated W1 molecule and the catalytic triad Thr-
57*, Lys-10*, and His-256 (with W3 and W2 in relay), which can abstract a
proton from the urate monoanion. The common site of W1 and the dioxygen
molecule is shown above the plane of urate (W1 in hydrogen-bonded to Thr-
57* and Asn-254 side chains). The hydrogen atoms are not displayed. These
ﬁgures were produced with the visualization software InsightII (Accelrys, San
Diego, CA).
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need to be done to understand precisely how the enzyme
abstracts the N7 proton to yield the [N3 N7] dianion.
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